Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report by So, Brian J. et al.
BioMed Central
Journal of Hematology & Oncology
ssOpen AcceCase report
Complete clinical response of metastatic hepatocellular carcinoma 
to sorafenib in a patient with hemochromatosis: A case report
Brian J So, Tanios Bekaii-Saab, Mark A Bloomston and Tushar Patel*
Address: The Ohio State University Medical Center, 395 W. 12th Avenue, Columbus, OH 43210, USA
Email: Brian J So - brian.so@osumc.edu; Tanios Bekaii-Saab - tanios.bekaii-saab@osumc.edu; 
Mark A Bloomston - mark.bloomston@osumc.edu; Tushar Patel* - tushar.patel@osumc.edu
* Corresponding author    
Abstract
Hepatocellular carcinoma is rare, but increasing in prevalence in the United States. Recent studies
have shown that sorafenib, a multikinase inhibitor, can reduce tumor progression in patients with
this cancer. However, complete remission has not been observed. We report a case of a 78-year
old patient with unresectable metastatic hepatocellular carcinoma who had a rapid and complete
clinical response following therapy with sorafenib for six months. No evidence of disease
recurrence has been noted for 6 months after discontinuation of therapy.
Background
Hepatocellular carcinoma (HCC) is the third leading
cause of cancer death worldwide, with more than 600,000
cases diagnosed every year [1]. Most patients present with
advanced and multifocal disease at the time of diagnosis,
and the median survival in this setting is less than 6
months. Until recently, there were no effective treatments
for advanced HCC [2]. However, a recent phase III rand-
omized, placebo-controlled trial showed an improvement
in overall survival in patients with advanced HCC treated
with sorafenib compared to placebo controls [3]. Soraf-
enib has effects on tumor proliferation and angiogenesis.
The mechanism of action of sorafenib includes inhibition
of multiple kinase targets within the liver. These include
members of the Raf family of serine/threonine kinases,
and other tyrosine kinases such as Flt-3, kit, Ret, vascular
endothelial growth factor receptor 2 (VEGFR-2), vascular
endothelial growth factor receptor 3 (VEGFR-3) and plate-
let-derived growth factor receptor beta (PDGFR-β) [4,5].
The "addiction" of tumors to specific kinases has been
demonstrated in some cancers, and targeting these can
result in dramatic responses. However, the predominant
effect noted with sorafenib has been reduction in tumor
progression [3]. We report herein a case of a rapid and
complete remission in a patient with the use of sorafenib
in metastatic HCC.
Case Presentation
A 78-year-old man with a 25-year history of hereditary
hemochromatosis, with cirrhosis, hypertension, diabetes
mellitus, coronary artery disease, and chronic kidney dis-
ease (stage II) presented with a six month history of non-
productive cough and shortness of breath. The patient
also reported an approximately 30-pound weight loss
over the previous 4 months. A CT-scan demonstrated a
dominant right lobe liver mass and several other intrahe-
patic lesions as well as multiple lung nodules. PET/CT
confirmed that these lesions in the right and left lobes of
the liver, as well as a right hilar mass were hypermetabolic.
His alpha-feto protein was found to be 13,599 ng/mL. A
diagnosis of metastatic hepatocellular cancer was made
on the basis of the clinical presentation, imaging studies
and elevated tumor markers. His Eastern Cooperative
Oncology Group (ECOG) performance status was 2.
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daily dosing. The patient tolerated the therapy well with
minimal toxicities, except for the onset of grade 1
diarrhea, which was well controlled medically without
dose reduction. A CT scan of the liver obtained after one
month of therapy showed a significant reduction of
tumor-burden with a decrease in the size of the mass in
the right lobe of the liver from 4.5 × 5.0 cm to 3.9 × 4.3
cm. Similarly, a CT scan of the chest revealed almost com-
plete resolution of the pulmonary nodules, with only one
0.4 cm nodule in the right apex. Concomitantly, there was
a dramatic reduction in the patient's alpha-fetoprotein to
4.5 ng/mL. The patient's follow-up visit the following
month continued to show that the patient was tolerating
his medication well. His functional status continued to
improve (ECOG 1). A repeat CT-scan of the abdomen
after 5 months showed further reduction in the liver
tumor, with a lesion in the right lobe measuring only 2.6
× 3.4 cm, and a repeat PET-scan did not show any evi-
dence of a hypermetabolic lesion in the liver 1. The
patient continued sorafenib for a total 6-month course,
and subsequent alpha-fetoprotein monitoring was per-
formed to assess for sustained response 2. At follow-up six
months after completion of the sorafenib treatment, there
was no clinical evidence of recurrence, alpha-fetoprotein
remained within normal limits and CT imaging contin-
ued to show evidence of complete remission.
Conclusion
Advanced metastatic HCC continues to portend a poor
prognosis with few therapeutic options [2]. Sustained
complete remission has been reported in metastatic HCC
only following aggressive surgical resection and cytotoxic
chemotherapy. This case represents the first known com-
plete response to sorafenib in metastatic HCC.
The SHARP (Sorafenib HCC Assessment Randomized
Protocol) trial was instrumental in showing the efficacy of
sorafenib on the overall survival of patients with HCC. An
increase of 44% in overall survival was seen, and a time-
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Positron Emission Tomography imaging scan prior to and following therapy. The top panels represent a coronal 
view whereas the bottom panels represent a horizontal section through the liver. (A) Pre-treatment imaging shows diffuse 
uptake in the liver, and lungs. (B) Subsequent imaging after 20 weeks of therapy with sorafenib reveals loss of uptake in these 
regions consistent with a dramatic reduction on tumor burden.
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to 2.8 months seen in the placebo group. Of the 299
patients randomized to receive sorafenib therapy in this
study, none showed complete response, 7 (2.3%) showed
partial response, and the majority, 211 (71%) showed sta-
ble disease [3]. Similarly complete remission has not been
observed in clinical trials of sorafenib in patients with
renal cell carcinoma. Preliminary studies have shown an
anti-tumor activity of sorafenib in a variety of tumor types
such as renal cell carcinoma, melanoma, thyroid cancer,
ovarian cancer, sarcoma, and pancreatic cancer. None of
these tumor types is characterized by elevated alpha-feto-
protein or imaging characteristics observed in our patient.
The case illustrates a patient who had a rapid and com-
plete response to sorafenib therapy, based on imaging and
tumor marker response. The response to therapy was
unlike that seen in reported clinical trials of sorafenib. In
the SHARP trial, 83% of the 902 patients in the study had
protocol deviation due to a variety of reasons. The original
dosing of sorafenib called for 400 mg, twice daily dosing.
Our patient was able to tolerate the complete dose
throughout the entire 6 month course without interrup-
tion or dose reduction. While the mechanism of response
in our patient is unclear, it is conceivable that his tumor
was strongly dependent for survival on one or more of the
receptor tyrosine kinases that are inhibited by sorafenib.
Although this phenomenon has been noted in some other
solid tumors such as gastrointestinal stromal tumors, we
do not have any direct evidence of this in our patient.
Moreover, it is unknown how the patient's underlying
hemochromatosis may have contributed to this response
due to the lack of reported experience with treatment of
HCC in this condition.
In conclusion, this case demonstrates that dramatic thera-
peutic responses are possible with the use of sorafenib for
the treatment of metastatic HCC. Our patient's apparent
complete response is certainly unusual. We speculate that
a subset of patients capable of attaining a complete remis-
sion will be identified as more patients with advanced
metastatic HCC undergo therapy with sorafenib. The
durability of such a robust response is yet to be deter-
mined.
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Temporal changes in alpha-feto-protein expressionFigure 2
Temporal changes in alpha-feto-protein expression. 
The duration of treatment with sorafenib is indicated in the 
gray bar. Initiation of sorafenib resulted in a dramatic reduc-
tion in serum AFP levels.
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